Xymedone produced therapeutic effect in patients with atopic bronchial asthma. The drug action was manifested by a decrease in the IgE level and an increase in gamma-interferon level. Adding xymedone to lymphocytes cultivated with phytohemagglutinin revealed stimulating action of this drug on the delayed-type hypersensitivity. Mechanisms involved in the immunotropic action of xymedone are discussed.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Exploring Social Health in Patients with Atopic Dermatitis: An Observational, Cross-sectional, Questionnaire Based Study on Social Participation and Emotional Support.
Acta Derm Venereol
January 2025
Department of Dermatology, University Medical Center Groningen, Groningen, The Netherlands.
Association between allergic diseases and mucosal healing in ulcerative colitis.
Sci Rep
January 2025
Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Ehime, Japan.
Allergic diseases and ulcerative colitis (UC) share pathophysiological similarities. This study aimed to investigate the unclear association between allergic diseases and mucosal healing (MH), an important factor in the prognosis of UC. We studied 289 Japanese patients with UC.
View Article and Find Full Text PDFTapinarof Improved Outcomes and Sleep for Patients and Families in Two Phase 3 Atopic Dermatitis Trials in Adults and Children.
Dermatol Ther (Heidelb)
January 2025
Dermavant Sciences, Inc., Morrisville, NC, USA.
Introduction: Tapinarof is a topical aryl hydrocarbon receptor (AhR) agonist in development for the treatment of atopic dermatitis (AD). In two phase 3 trials (ADORING 1 and 2), tapinarof cream 1% once daily (QD) demonstrated significant efficacy and was well tolerated in patients down to age 2 years with AD. Here, we evaluate patient-reported outcomes (PROs), including family impact, with tapinarof in ADORING 1 and 2.
View Article and Find Full Text PDFRegistries in allergy: Structure, target groups, and key findings of allergy-focused registries in Germany.
Allergol Select
December 2024
Division of Allergy and Immunology, Department of Dermatology, Venerology and Allergology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
In allergology, clinical registries fill knowledge gaps of epidemiology, mechanisms of allergic diseases, and real-world treatment outcomes. Considering the continuous rise of allergic diseases worldwide, registries become increasingly important for the optimization and harmonization of patient care. In the current review, we present four ongoing allergy-focused registries initiated in Germany.
View Article and Find Full Text PDFSevere atopic dermatitis treated with Dupilumab in a CTLA-4-deficient patient: A case report and review of the literature.
SAGE Open Med Case Rep
January 2025
Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Atopic dermatitis is a chronic inflammatory skin disease associated with immune dysregulation, particularly overexpression of T helper 2 cytokines. Cytotoxic T lymphocyte-associated antigen 4 deficiency, a primary immune disorder, can exacerbate atopic dermatitis. Dupilumab, an IL-4 and IL-13 receptor antagonist, has demonstrated efficacy in controlling severe, recalcitrant atopic dermatitis by mitigating T helper 2-driven inflammation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!